

Table S1. Codes used to identify the study population.

Study population	ICD-10	ICD-8	ICD-9-CM	ICD-10-GM	ICPC
Diagnosis					
Atrial fibrillation	I48	427.93, 427.94	427.31 427.32	I48	K78
Exclusion					
Valvular atrial fibrillation	I05.0, I05.1, I05.2, I05.8, I05.9, I06, I08, I34, I35 Z95.2, Z95.3, Z95.4	424.0, 424.1, 394, 395, 396 494.0	394.0, 394.1, 394.2, 394.9, 395, 396, 424, V42.2, V43.3	I05.0, I05.1, I05.2, I05.8, I05.9, Z95.2, Z95.3, Z95.4, I06, I08, I34, I35	K71, K83

^aPatients were considered to have a diagnosis of NVAf according to 1) A diagnosis of NVAf was linked to the first prescriptions of the DOAC (BIFAP, Mondriaan), if this was not possible then 2) a medical code for NVAf ±3 months around the index date either in GP-records (CPRD, SIDIAP, BIFAP, Mondriaan) or claims records (AOK Nordwest, Bavarian CD) database) or 3) a medical code for NVAf prior to index date to 3 months after the index date in case of Hospital-record database (DNR, EGB).

Table S2. Codes used to identify chronic kidney disease.

	ICD-10	ICD-8	ICD-9-CM	ICD-10-GM	ICPC
Diagnosis					
Severe renal impairment/Chronic and acute kidney disease	I12, I13, N00, N01, N03, N04, N05, N07, N08, N10, N11, N12, N14, N17, N18.4, N18.5, N18.9 N19, Q61, Z94.0	(Charlson Index) 403; 404; 580-584; 590.09	403.01 403.11 403.91 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 580.8, 581, 582, 585.3, 584, 585.5, 585.5, 585.6, 585.9, 586, 588, 590.1, 590.20, 590.8, 753.1 V42.0	I12 I13 N00 N01 N03 N04 N05 N07 N08, N10, N11, N12, N14, N17, N18.4, N18.5, N18.9 N19, Q61, Z94.0	U99.01 <u>ICPC codes extension in BIFAPⁱ</u> U99.10-CHRONIC KIDNEY DISEASE U99.9-ACUTE KIDNEY DISEASE

Table S3. Baseline characteristics for all new users of direct oral anticoagulants stratified by prior use of oral anticoagulants by database.

	MONDRIAAN	DANISH NATIONAL REGISTRIES	AOK NORDWEST	BAVARIAN CLAIMS	BIFAP	SIDIAP	CPRD	EGB
ALL USERS	460	44876	21718	84276	14161	11962	6931	2021
WITHOUT PREVIOUS USE OF OACs	303 (65.9%)	31931 (71.1%)	13509 (62.2%)	55515 (65.9%)	8807 (62.2%)	5630 (47.1%)	5712 (82.4%)	1456 (72.0%)
Female	127 (41.9%)	14451 (45.3%)	7184 (53.2%)	28551 (51.4%)	4100 (46.6%)	2462 (43.7%)	2526 (44.2%)	630 (43.3%)
Male	176 (58.1%)	17480 (54.7%)	6325 (46.8%)	26964 (48.6%)	4707 (53.4%)	3168 (56.3%)	3186 (55.8%)	826 (56.7%)
AGE in years, mean (SD)	69.9 (11.6)	73.3 (11.2)	73.9 (11.8)	73.4 (11.5)	75.4 (10.8)	73 (12)	74.8 (11.0)	72.1 (12.3)
CO-MORBIDITIES	-	19883 (62.3%)	11251 (83.3%)	46289 (83.4%)	3718 (42.2%)	2476 (44.0%)	3458 (60.5%)	677 (46.5%)
CONCOMITANT MEDICATION	0 (0.0%)	12089 (37.9%)	1426 (10.6%)	20881 (37.6%)	1192 (13.5%)	461 (8.2%)	437 (7.7%)	602 (41.3%)
WITH PREVIOUS USE OF OACs	157 (34.1%)	12945 (28.8%)	8209 (37.8%)	28761 (34.1%)	5354 (37.8%)	6332 (52.9%)	1219 (17.6%)	565 (28%)
Female	62 (39.5%)	5880 (45.4%)	4466 (54.4%)	15519 (54.0%)	2655 (49.6%)	3136 (49.5%)	523 (42.9%)	237 (41.9%)
Male	95 (60.5%)	7065 (54.6%)	3743 (45.6%)	13242 (46.0%)	2699 (50.4%)	3196 (50.5%)	696 (57.1%)	328 (58.1%)
AGE in years, mean (SD)	70.1 (10.5)	75.2 (10.1)	76.4 (9.9)	76.7 (9.6)	76.3 (9.8)	76.0 (9.7)	74.3 (10.9)	74.6 (11.0)
CO-MORBIDITIES	-	10076 (77.8%)	7674 (93.4%)	26999 (93.9%)	3147 (58.8)	3961 (62.6%)	879 (72.1%)	365 (64.6%)
CONCOMITANT MEDICATION	0 (0.0%)	5367 (41.5%)	658 (8.0%)	13749 (47.8%)	641 (12.0%)	181 (2.9%)	88 (7.2%)	115 (20.3%)

Table S4. Number of new users for all DOACs and each type of DOAC by database

	MONDRIAAN		DANISH NATIONAL REGISTRIES		AOK NORDWEST		BAVARIAN CLAIMS		BIFAP		SIDIAP		CPRD		EGB	
	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
All DOACs	460	(100)	44876	(100)	21718	(100)	84276	(100)	14161	(100)	11962	(100)	6931	(100)	2021	(100)
Dabigatran	99	(21,5)	23308	(51.9)	3968	(18.3)	14729	(17.4)	3863	(27.3)	4784	(40.0)	1265	(18.3)	479	(23.7)
Apixaban	72	(15,7)	10358	(23.1)	5460	(25.1)	17339	(20.6)	3693	(26.1)	2728	(22.8)	2060	(29.7)	396	(19.6)
Rivaroxaban	289	(62,8)	11210	(25.0)	12290	(56.6)	52208	(61.9)	6605	(46.6)	4450	(37.2)	3606	(52.0)	1146	(56.7)

Table S5. Switchers and discontinuers: all DOAC, by type of DOAC and by sex and age in each database, for the complete study period.

	Netherlands (Mondriaan)	Denmark (DNR)	Germany (AOK NORDWEST)	Germany (Bavarian claims)	Spain (BIFAP)	Spain (SIDIAF)	United Kingdom (CPRD)	France (EGB)
All DOACs	460	44876	21718	84276	14161	11962	6931	2021
SWITCHERS (all study period)	11 (2.4%)	5665 (12.6%)	3491 (16.1%)	11791 (14.0%)	1249 (8.8%)	753 (6.3%)	457 (6.6%)	312 (15.4%)
Female	4 (2.1%)	2544 (12.5%)	1860 (16.0%)	6332 (14.4%)	621 (9.2%)	373 (6.7%)	232 (7.6%)	155 (17.9%)
Male	7 (2.6%)	3121 (12.7%)	1631 (16.2%)	5459 (13.6%)	628 (8.5%)	380 (6.0%)	225 (5.8%)	157 (13.6%)
<75 year	7 (2.3%)	3419 (14.9%)	1501 (17.1%)	5297 (14.4%)	540 (9.7%)	336 (6.5%)	204 (6.6%)	131 (13.2%)
75-79 years	3 (4.9%)	879 (12.1%)	830 (17.3%)	2798 (15.6%)	256 (9.7%)	150 (6.7%)	100 (7.7%)	65 (18.4%)
>=80 years	1 (1.0%)	1367 (9.3%)	1160 (14.2%)	3696 (12.5%)	453 (7.6%)	267 (5.9%)	153 (6.1%)	116 (17.2%)
Female <75 year	1 (0.8%)	1260 (15.8%)	606 (17.6%)	2368 (15.6%)	222 (11.2%)	142 (7.9%)	82 (8.1%)	46 (15.4%)
Female 75 -79 years	3 (12.5%)	452 (12.9%)	472 (17.6%)	1582 (16.3%)	138 (10.1%)	74 (6.6%)	58 (9.4%)	31 (20.4%)
Female >=80 years	0 (0.0)	832 (9.4%)	782 (14.2%)	2382 (12.4%)	261 (7.7%)	157 (5.9%)	92 (6.5%)	78 (18.7%)
Male <75 year	8 (4.2%)	2159 (14.4%)	895 (16.7%)	2929 (13.6%)	318 (8.9%)	194 (5.7)	122 (5.8%)	85 (12.2%)
Male 75 -79 years	0 (0.0)	427 (11.4%)	358 (17.1%)	1216 (14.7%)	118 (9.2%)	76 (6.8%)	42 (6.2%)	34 (16.9%)
Male >=80 years	1 (2.3%)	535 (9.2%)	378 (14.4%)	1314 (12.6%)	192 (7.5%)	110 (5.9%)	61 (5.5%)	38 (14.8%)
DISCONTINUERS(all study period)	241 (52.4%)	17795 (39.6%)	11170 (51.4%)	66905 (79.4%)	4540 (32.1%)	4698 (39.35)	1228 (17.7%)	621 (30.7%)
Female	107 (56.6%)	7606 (37.4%)	5905 (50.7%)	34853 (79.4%)	2099 (31.1%)	2102 (37.5%)	499 (16.4%)	248 (28.6%)
Male	134 (49.4%)	10189 (41.5%)	5265 (52.3%)	32052 (79.7%)	2441 (33.0%)	2596 (40.8%)	729 (18.8%)	373 (32.3%)
<75 year	167 (61.6%)	9640 (41.9%)	4375 (49.7%)	28985 (79.1%)	1817 (32.7%)	2228 (43.1%)	563 (18.1%)	340 (34.2%)
75-79 years	31 (10.0%)	2766 (38.1%)	2331 (47.7%)	13975 (77.7%)	848 (32.0%)	833 (37.0%)	196 (15.1%)	95 (26.9%)
>=80 years	43 (70.5%)	5389 (36.8%)	4464 (54.8%)	23945 (80.8%)	1875 (31.5%)	1637 (36.0%)	469 (18.6%)	186 (27.6%)
Female <75 year	70 (70.7%)	3071 (38.5%)	1636 (47.4%)	11811 (77.9%)	619 (31.1%)	724 (40.4%)	145 (14.3%)	99 (33.1%)
Female 75 -79 years	12 (50.0%)	1292 (36.9%)	1288 (47.9%)	7530 (77.4%)	437 (31.9%)	408 (36.3%)	92 (14.9%)	37 (24.3%)
Female >=80 years	25 (44.6%)	3243 (36.6%)	2981 (54.1%)	15512 (80.8%)	1043 (30.7%)	970 (36.2%)	262 (18.5%)	112 (26.9%)
Male <75 year	97 (50.8%)	6569 (43.8%)	2739 (51.2%)	17174 (79.9%)	1198 (33.6%)	1504 (44.6%)	418 (19.9%)	241 (34.6%)
Male 75 -79 years	19 (51.4%)	1474 (39.2%)	1043 (49.7%)	6445 (78.1%)	411 (32.2%)	425 (37.8%)	104 (15.3%)	58 (28.9%)
Male >=80 years	18 (41.9%)	2146 (37.0%)	1483 (56.5%)	8433 (80.7%)	832 (32.5%)	667 (35.7%)	207 (18.8%)	74 (28.8%)
CKD n [ndiscontinuers (%)]	0	2055 [758 (36.9%)]	4377 [2286(52.2%)]	20287 [15840 (78.1%)]	226 [67 (29.6%)]	1837 [641 (34.9%)]	51 [8 (15.7%)]	107 [39 (36.4%)]

Table S6. Number of New DOACs users, switchers and discontinuers with NVAF excluding those with other approved DOAC indications.

	Netherlands (Mondriaan)	Denmark (NRD)	Germany (AOK NORDWEST)	Germany (Bavarian claims)	Spain (BIFAP)	Spain (SIDIAP)	United Kingdom (CPRD)	France (EGB)
All DOACs	NOT APPLICABLE - NO patients with other indications	41708	18239	70970	13719	10287	6611	1483
Number of switchers related to any DOACs N ^o (%)		5240 (12.6)	2880 (15.8)	9824 (13.8)	1200 (8.7)	641 (6.2)	428 (6.5)	227 (15.3)
Switchers at 1-3 months N ^o (%)		2656 (6.4)	1012 (5.5)	5159 (7.3)	827 (6.0)	344 (3.3)	273 (4.1)	121 (8.2)
Switchers at 1-6 months N ^o (%)		3566 (8.4)	1520 (8.3)	6289 (8.9)	959 (7.0)	419 (4.1)	338 (5.1)	153 (10.3)
Switchers at 1-12 months N ^o (%)		4350 (10.4)	2024 (11.1)	7815 (11.0)	1077 (7.8)	525 (5.1)	389 (5.9)	188 (12.7)
Number of discontinuers related to any DOACs N ^o (%)		16523 (39.6)	9441 (51.8)	56478 (79.6)	4392 (32.0)	4096 (39.8)	1155 (17.5)	448 (30.2)
Discontinuers at 1-3 months N ^o (%)		3424 (8.2)	2654 (14.5)	27586 (38.9)	1743 (12.7)	1777 (17.3)	592 (9.0)	205 (13.8)
Discontinuers at 1-6 months N ^o (%)		7165 (17.2)	5016 (27.5)	35148 (49.5)	2592 (18.9)	2438 (23.7)	831 (12.6)	293 (19.8)
Discontinuers at 1-12 months N ^o (%)		11357 (27.2)	7098 (38.9)	45344 (63.9)	3495 (25.5)	3151 (30.6)	1041 (15.7)	385 (26.0)
Dabigatran		21885	3405	12604	3749	4200	1223	358
Number of switchers related to Dabigatran N ^o (%)		3672 (16.8)	951 (27.9)	3343 (26.5)	473 (16.6)	394 (9.4)	173 (14.1)	88 (24.6)
Switchers at 1-3 months N ^o (%)		1705 (7.8)	300 (8.8)	1581 (12.5)	301 (8.0)	192 (4.6)	97 (7.9)	39 (10.9)
Switchers at 1-6 months N ^o (%)		2339 (10.7)	454 (13.3)	2007 (15.9)	358 (9.5)	235 (5.6)	130 (10.6)	50 (14.0)
Switchers at 1-12 months N ^o (%)		2924 (13.4)	595 (17.5)	2501 (19.8)	409 (10.9)	307 (7.3)	152 (12.4)	69 (19.3)
Number of discontinuers related to Dabigatran N ^o (%)		11000 (50.3)	2064 (60.6)	8992 (71.3)	1564 (41.7)	2087 (49.7)	342 (28.0)	135 (37.7)
Discontinuers at 1-3 months N ^o (%)		2197 (10.0)	424 (12.4)	3275 (26.0)	582 (15.5)	850 (20.2)	140 (11.4)	50 (14.0)
Discontinuers at 1-6 months N ^o (%)		4503 (20.6)	797 (23.4)	4032 (32.0)	857 (22.9)	1159 (27.6)	219 (17.9)	79 (22.1)
Discontinuers at 1-12 months N ^o (%)		7093 (32.4)	1167 (34.3)	5264 (41.8)	1184 (31.6)	1516 (30.1)	285 (23.3)	109 (30.4)
Apixaban		9669	4622	14503	3585	2299	1967	279
Number of switchers related to Apixaban N ^o (%)		497 (5.1)	297 (6.4)	827 (5.7)	189 (5.3)	69 (3.0)	54 (2.7)	19 (6.8)
Switchers at 1-3 months N ^o (%)		313 (3.2)	163 (3.5)	579 (4.0)	142 (4.0)	45 (1.2)	37 (1.9)	14 (5.0)
Switchers at 1-6 months N ^o (%)		398 (4.1)	215 (4.6)	680 (4.7)	162 (4.5)	54 (2.3)	44 (2.2)	19 (6.8)
Switchers at 1-12 months N ^o (%)		472 (4.9)	274 (5.9)	794 (5.5)	183 (5.1)	63 (2.7)	50 (2.5)	19 (6.8)
Number of discontinuers related to Apixaban N ^o (%)		2297 (23.7)	2102 (45.5)	11496 (79.3)	827 (23.1)	636 (27.7)	253 (12.9)	56 (20.1)
Discontinuers at 1-3 months N ^o (%)		542 (5.6)	667 (14.4)	6216 (42.8)	349 (9.7)	303 (13.2)	141 (7.2)	36 (12.9)
Discontinuers at 1-6 months N ^o (%)		1223 (12.6)	1303 (28.2)	8054 (55.5)	557 (15.5)	426 (18.5)	196 (10.0)	45 (16.1)
Discontinuers at 1-12 months N ^o (%)		1917 (19.8)	1817 (39.3)	10124 (69.8)	753 (21.0)	544 (23.7)	238 (12.1)	55 (19.7)

	Netherlands (Mondriaan)	Denmark (NRD)	Germany (AOK NORDWEST)	Germany (Bavarian claims)	Spain (BIFAP)	Spain (SIDIAP)	United Kingdom (CPRD)	France (EGB)
Rivaroxaban		10154	10212	43863	6385	3788	3421	846
Number of switchers related to Ribaroxavan N° (%)		1071 (10.5)	1632 (16.0)	5654 (12.9)	538 (8.4)	178 (4.7)	201 (5.9)	120 (14.2)
Switchers at 1-3 months N° (%)		638 (6.3)	549 (5.4)	2999 (6.8)	384 (6.0)	107 (2.8)	139 (4.1)	68 (8.0)
Switchers at 1-6 months N° (%)		829 (8.2)	851 (8.3)	3602 (8.2)	439 (6.9)	130 (3.4)	164 (4.8)	84 (9.9)
Switchers at 1-12 months N° (%)		954 (9.4)	1155 (11.3)	4520 (10.3)	485 (7.6)	155 (4.1)	187 (5.5)	100 (11.8)
Number of discontinuers related to any Rivaroxaban N° (%)		3226 (31.8)	5275 (51.6)	35990 (82.0)	2001 (31.3)	1373 (36.2)	560 (16.4)	257 (30.4)
Discontinuers at 1-3 months N° (%)		685 (6.7)	1563 (15.3)	18095 (41.2)	812 (17.7)	624 (16.5)	311 (9.1)	119 (14.1)
Discontinuers at 1-6 months N° (%)		1439 (14.2)	2916 (28.5)	23062 (52.6)	1178 (18.4)	853 (22.5)	416 (12.2)	169 (20.0)
Discontinuers at 1-12 months N° (%)		2347 (23.1)	4114 (40.3)	29956 (68.3)	1558 (24.4)	1091 (20.8)	518 (15.1)	221 (26.1)

Table S7. Number of New DOACs users with NVAF (sensitivity analyses taking account a gap of 60 days)

	Netherlands (Mondriaan)	Denmark (NRD)	Germany (AOK NORDWEST)	Germany (Bavarian claims)	Spain (BIFAP)	Spain (SIDIAP)	United Kingdom (CPRD)	France (EGB)
All DOACs	460	44876	NA	NA	14161	11962	6931	2021
Number of discontinuers related to any DOACs N° (%)		10620 (23.7)			2816 (20.0)	4081 (31.1)	779 (11.2)	470 (23.3)
Discontinuers at 1-3 months N° (%)	107 (23.3)	2972 (6.6)			1054 (7.4)	1717 (14.3)	380 (5.5)	221 (10.9)
Discontinuers at 1-6 months N° (%)	140 (30.4)	5793 (12.9)			1561 (11.0)	2355 (19.7)	549 (7.9)	321 (15.9)
Discontinuers at 1-12 months N° (%)	170 (37.0)	8374 (18.7)			2135 (15.1)	3034 (25.4)	708 (10.2)	417 (20.6)
Dabigatran	99	23308			3863	4784	1265	479
Number of discontinuers related to Dabigatran N° (%)		7011 (30.1)			1032 (26.7)	2030 (42.4)	244 (19.3)	139 (29.0)
Discontinuers at 1-3 months N° (%)	27 (27.3)	1948 (8.3)			346 (9.0)	806 (16.8)	97 (7.7)	54 (11.3)
Discontinuers at 1-6 months N° (%)	35 (35.4)	3724 (16.0)			508 (13.1)	1089 (22.8)	159 (12.6)	86 (18.0)
Discontinuers at 1-12 months N° (%)	48 (48.5)	5333 (22.9)			710 (18.4)	1402 (29.3)	211 (16.7)	117 (24.4)
Apixaban	72	10358			3693	2728	2060	396
Number of discontinuers related to Apixaban N° (%)		1285 (12.1)			528 (14.3)	648 (23.7)	136 (6.6)	54 (13.6)
Discontinuers at 1-3 months N° (%)	10 (13.9)	393 (3.8)			215 (5.8)	284 (10.4)	75 (3.6)	33 (8.3)
Discontinuers at 1-6 months N° (%)	18 (25.0)	818 (7.9)			346 (9.4)	401 (14.7)	104 (5.0)	43 (10.9)
Discontinuers at 1-12 months N° (%)	20 (27.8)	1154 (11.1)			486 (13.2)	538 (19.7)	128 (6.2)	54 (13.6)
Rivaroxaban	279	11210			6605	4450	3606	1146
Number of discontinuers related to any Rivaroxaban N° (%)		2324 (20.7)			1256 (19.0)	1403 (31.5)	399 (11.1)	277 (24.2)
Discontinuers at 1-3 months N° (%)	70 (25.1)	631 (5.6)			439 (6.6)	627 (14.9)	208 (5.8)	134 (11.7)
Discontinuers at 1-6 months N° (%)	87 (31.2)	1251 (11.1)			707 (10.7)	865 (19.4)	286 (7.9)	192 (16.8)
Discontinuers at 1-12 months N° (%)	102 (36.6)	1887 (16.8)			939 (14.2)	1094 (24.6)	369 (10.2)	246 (21.5)

Table S8. Number of New DOACs users with NVAf excluding those with other approved DOAC indications (sensitivity analyses taking account a gap of 60 days)

	Netherlands (Mondriaan)	Denmark (NRD)	Germany (AOK NORDWEST)	Germany (Bavarian claims)	Spain (BIFAP)	Spain (SIDIAP)	United Kingdom (CPRD)	France (EGB)
All DOACs	NOT APPLICABLE - NO patients with other indications	41708	NA	NA	13719	10287	6611	1483
Number of discontinuers related to any DOACs N ^o (%)		9824 (23.5)			2730 (19.9)	3573 (34.7)	737 (11.1)	339 (22.9)
Discontinuers at 1-3 months N ^o (%)		2770 (6.6)			1014 (7.4)	1489 (14.5)	357 (5.4)	156 (10.5)
Discontinuers at 1-6 months N ^o (%)		5362 (12.8)			1514 (11.0)	2056 (20.0)	517 (7.8)	226 (15.2)
Discontinuers at 1-12 months N ^o (%)		7711 (18.5)			2070 (15.1)	2644 (25.7)	668 (10.1)	297 (20.0)
Dabigatran		21885			3749	4200	1223	358
Number of discontinuers related to Dabigatran N ^o (%)		6602 (30.2)			1000 (26.7)	1820 (43.3)	239 (19.5)	100 (27.9)
Discontinuers at 1-3 months N ^o (%)		1842 (8.4)			333 (8.9)	715 (17.0)	93 (7.6)	39 (10.9)
Discontinuers at 1-6 months N ^o (%)		3509 (16.0)			493 (13.1)	971 (23.1)	155 (12.7)	61 (17.0)
Discontinuers at 1-12 months N ^o (%)		5020 (22.9)			678 (18.1)	1257 (29.3)	206 (16.8)	84 (23.5)
Apixaban		9669			3585	2299	1967	279
Number of discontinuers related to Apixaban N ^o (%)		1176 (12.2)			520 (14.5)	536 (23.3)	127 (6.5)	40 (14.3)
Discontinuers at 1-3 months N ^o (%)		364 (3.8)			211 (5.9)	236 (10.3)	69 (3.5)	26 (9.3)
Discontinuers at 1-6 months N ^o (%)		745 (7.7)			340 (9.5)	337 (14.7)	96 (4.9)	33 (11.8)
Discontinuers at 1-12 months N ^o (%)		1048 (10.8)			479 (13.4)	443 (19.3)	119 (6.0)	40 (14.3)
Rivaroxaban		10154			6385	3788	3421	846
Number of discontinuers related to any Rivaroxaban N ^o (%)		2046 (20.1)			1210 (18.9)	1217 (32.1)	371 (10.8)	199 (23.5)
Discontinuers at 1-3 months N ^o (%)		564 (5.5)			470 (7.4)	538 (14.2)	195 (5.7)	91 (10.8)
Discontinuers at 1-6 months N ^o (%)		1108 (10.9)			681 (10.7)	748 (19.7)	266 (7.8)	132 (15.6)
Discontinuers at 1-12 months N ^o (%)		1643 (16.2)			904 (14.2)	944 (24.9)	343 (10.0)	173 (20.4)